反应详情

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (100 mg; 0.24 mmol) and β-alanine (43.2 mg; 0.48 mmol) to give Example 127 as a white solid. 1H NMR: (DMSO-d6, 400 MHz) δ 8.75 (2H, dd, J=4.5, 1.6 Hz), 7.97 (2H, d, J=8.1 Hz), 7.91 (1H, td, J=7.6, 1.7 Hz), 7.76-7.69 (1H, m), 7.61 (2H, dd, J=4.5, 1.7 Hz), 7.58 (2H, d, J=8.1 Hz), 7.55-7.45 (2H, m), 3.87 (2H, s), 2.81-2.68 (2H, m), 2.39 (2H, t, J=6.7 Hz). LC/MS (Method C): 484 (M+H)+. HPLC (Method F) Rt 2.83 min (Purity: 99.2%).

1. customobtained